Merck to phase out osteoporosis specialty team

Share this article:

Merck plans to eliminate its osteoporosis specialty team at the end of the year, ahead of the February 2008 patent expiration of its bone density blockbuster Fosamax.

A total of 250 positions from the osteoporosis team, including some sales jobs, will be impacted, according to Merck spokeswoman Amy Rose.

“We informed this group of individuals well in advance so that we could work with them to find other opportunities within Merck that fit their skills and interest,” Rose told MM&M.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.